CompoAtlas

Cutgenic for Women 90 caps

Food supplement declared in France, declaration No 2022-12-1298

Cutgenic for Women 90 caps (PROZIS) is a food supplement declared in France. Status: withdrawn from the market on 22 December 2025. Main ingredients: Phaseolus vulgaris 300 mg per day, Cinnamomum cassia 150 mg per day, Ilex paraguariensis 150 mg per day, Glycine max. 99 mg per day, Taraxacum campylodes 75 mg per day. 1 rule of use applies to its ingredients (limits and warnings).

Brand
PROZIS
Food business operator placing the product on the market
Prozis.Com, S.A.
Status
Withdrawn from the market on 22 December 2025
Form
Capsule
Daily dose
3 gélules
Directions for use
Prendre 3 gélules par jour.
Intended populations
Men, Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, History of breast cancer, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking medication
Objectives stated by the manufacturer (these are not authorised claims)
Slimming / Fat burner

Declaration 190653, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Phaseolus vulgaris L.GraineExtrait sec aqueux300 mg
Cinnamomum cassia (Nees & T.Nees) J.PreslEcorceExtrait sec hydroalcoolique150 mg
Ilex paraguariensis A. St.-Hil.FeuillePoudre (de plantes séchées ou broyées)150 mg
Glycine max. (L.) Merr.GraineExtrait sec hydroalcoolique99 mg
Taraxacum campylodes G.E.HaglundRacinePoudre (de plantes séchées ou broyées)75 mg
Euterpe oleracea Mart.FruitExtrait sec aqueux25 mg
Piper nigrum L.FruitExtrait sec hydroalcoolique15 mg

Other active ingredients

NamePer day
Acétylcarnitinenot declared
Tyrosinenot declared
Resvératrolnot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
Chlorure de chromeChromiumno limit (insufficient data)25 µg

Additives

E460, E470b, E122, E172, E551

Other ingredients

gélatine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Utilisation réservée aux adultes. Déconseillé aux femmes ayant des antécédents personnels ou familiaux de cancer du sein. Déconseillé aux enfants et aux femmes enceintes ou allaitantes. Consultez votre médecin si vous prenez des médicaments. Le colorant Azorubine peut avoir des effets indésirables sur l'activité et l'attention chez les enfants. Ne pas dépasser la dose journalière recommandée. Ce produit ne doit pas remplacer une alimentation variée et équilibrée et un mode de vie sain. Maintenir hors de la portée des enfants. Conserver bien fermé dans l'emballage d'origine dans un endroit frais et sec, à l'abri de la lumière directe du soleil.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Cinnamomum cassia (Nees & T.Nees) J.Presl
    Read the warning, when it applies and the studies cited

    CASSIA - CINNAMOMUM AROMATICUM

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Appetite loss; Digestive disturbances/Indigestion; Traditional Chinese Medicine claims.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Products providing 1 g or more of branch bark, stem bark and/or trunk bark, per day

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Sources cited by Health Canada (2)
    • Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): American Botanical Council; 2000.
    • WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Gardner and McGuffin 2013; Brinker 2010).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Contraindications

    Applies to products providing 1 g or more of branch bark, stem bark and/or trunk bark, per day.

    Do not use if you are pregnant (PPRC 2020; Brinker 2010; BHC 2006; Chen and Chen 2004; Blumenthal 2000, 1998).

    Sources cited by Health Canada (6)
    • BHC 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drugs - Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
    • Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): American Botanical Council; 2000.
    • Blumenthal M, editor. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin (TX): American Botanical Council in cooperation with Integrative Medicine Communications; 1998.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.
    • PPRC 2020: Pharmacopoeia of the People's Republic of China. Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.

    Condition of application: Traditional Chinese Medicine claims.

    Do not use if you have excess heat, blood heat or deficiency, or yin-deficient fire (PPRC 2020; Bensky et al. 2004; Chen and Chen 2004).

    Sources cited by Health Canada (3)
    • Bensky D, Clavey, Stöger E, Gamble A. Chinese Herbal Medicine: Materia Medica. 3rd edition. Seattle (WA): Eastland Press, Incorporated; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.
    • PPRC 2020: Pharmacopoeia of the People's Republic of China. Volume 1, English edition. Beijing (CN): The State Pharmacopoeia Commission of the People's Republic of China; 2020.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Gardner and McGuffin 2013; Blumenthal 2000; WHO 1999).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): American Botanical Council; 2000.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Raton (FL): Taylor and Francis Group; 2013.
    • WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.

    Health Canada monograph dated 30 May 2025

  • Glycine max. (L.) Merr.
    Read the warning, when it applies and the studies cited
  • Taraxacum campylodes G.E.Haglund
    Read the warning, when it applies and the studies cited

    DANDELION - TARAXACUM OFFICINALE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a liver or biliary disorder or an intestinal obstruction (Brinker 2010; Godfrey et al. 2010; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (5)
    • Bradley PR, editor. 1992. British Herbal Compendium, Volume 1. Bournemouth (GB): British Herbal Medicine Association.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products. 2nd edition. Exeter (GB): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Godfrey A, Saunders P, Barlow K, Gowan M. Principles and Practices of Naturopathic Botanical Medicine: Volume 1: Botanical Medicine Monographs, 1st edition. Toronto (ON): CCNM Press Inc.; 2010.
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Consulté le 14 mars 2024]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf

    Condition of application: Constipation, Flushing of the urinary tract, Indigestion, and Loss of appetite.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Applies to products providing 10 g or more of dried leaf or dried root or dried whole plant, per day or 10 mL or more of juice, per day.

    Do not use if you have diabetes or a blood pressure, kidney or cardiovascular disorder (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    Sources cited by Health Canada (8)
    • Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
    • Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Randomised trial
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
    • Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
    • Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
    • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
    • Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
    • Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.

    Do not use if you are taking heart medications or other products containing diuretics (Goksu et al. 2010; EMA 2009; Hunt et al. 2005; Green et al. 2002; Mujais and Katz 2000; Carlsen et al. 1990; Kuller et al. 1986; Artz et al. 1966).

    Sources cited by Health Canada (8)
    • Artz SA, Paes IC, Faloon WW. Hypokalemia-induced hepatic coma in cirrhosis. Occurrence despite neomycin therapy. Gastroenterology 1966;51(6):1046-1053. PubMed
    • Carlsen JE, Køber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. British Medical Journal 1990;300(6730):975-978. PubMed Randomised trial
    • EMA 2009: European Medicines Agency, Science Medicines Health. 12 November 2009. EMA/HMPC/212895/2008. Committee on Herbal Medicinal Products (HMPC) Community herbal monograph on Taraxacum officinale Weber ex Wigg., radix cum herba. Final. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-taraxacum-officinale-weber-ex-wigg-radix-cum-herba_en.pdf
    • Goksu E, Eken C, Karadeniz O, Kucukyilmaz O, Firt report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion. The American Journal of Emergency Medicine 2010;28:111.e1-111.e2
    • Green DM, Ropper AH, Kronmal RA, Psaty BM, Burke GL. Serum potassium level and dietary potassium intake as risk factors for stroke. Neurology 2002;59(3):314-320. PubMed
    • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith Jr. SC, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines, American College of Chest Physicians, International Society for Heart and Lung Transplantation, Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112(12):e154-235.
    • Kuller LH, Hulley SB, Cohen JD, Neaton J. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: a critical analysis. Circulation 1986;73(1):114-123. PubMed
    • Mujais SK, Katz AL. Potassium deficiency. In: Seldin & Giebisch's The Kidney: Physiology and Pathophysiology. Lippincott Williams and Wilkins; 2000. p1615.

    Health Canada monograph dated 25 July 2025

  • Euterpe oleracea Mart.
    Read the warning, when it applies and the studies cited

    ACAI – EUTERPE OLERACEA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (derMarderosian and Beutler 2008).

    Sources cited by Health Canada (1)
    • derMarderosian A, Beutler JA, editors. The Review of Natural Products. [Acai: Date of issue January 2008]. St Louis (MO): Facts and Comparisons, Wolters Kluwer Health; Printed in 2008 and Updated to April 2012.

    Health Canada monograph dated 24 April 2026

  • Tyrosine
    Read the warning, when it applies and the studies cited

    L-TYROSINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 30 January 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Brand : PROZIS

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Cutgenic for Women 90 caps (PROZIS): composition and regulation”, https://compoatlas.com/en/supplements/products/190653-cutgenic-for-women-90-caps, updated 15 November 2026.

Enter to analyse, Shift+Enter for a new line